Company Filing History:
Years Active: 2008-2009
Title: The Innovative Contributions of Bernard Riedl
Introduction
Bernard Riedl is a notable inventor based in Branford, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit RAF kinase. With a total of 2 patents, Riedl's work has the potential to impact the treatment of various diseases.
Latest Patents
Riedl's latest patents focus on the inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas. One of his patents details methods of treating tumors mediated by RAF kinase, utilizing substituted urea compounds. Another patent describes the compounds as aryl and heteroaryl substituted heterocyclic ureas of the formula A—NH—C(O)—NH—B, where A represents the aryl or hetaryl substituted heterocyclic group and B is an aryl or heteroaryl moiety. These compounds are designed to inhibit RAF kinase and are useful in treating diseases mediated by this kinase.
Career Highlights
Throughout his career, Riedl has worked with prominent companies in the pharmaceutical industry, including Bayer Pharmaceuticals Corporation and Bayer Healthcare LLC. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Riedl has collaborated with notable professionals in his field, including Jacques P. Dumas and Uday R. Khire. These collaborations have likely enhanced his research and development efforts.
Conclusion
Bernard Riedl's innovative work in the pharmaceutical sector, particularly in the inhibition of RAF kinase, showcases his contributions to medical science. His patents and collaborations reflect a commitment to advancing treatment options for patients.